Deregulation of Wnt/b-catenin pathway is a hallmark of major gastrointestinal cancers including hepatocellular carcinoma (HCC). The oncogenic role of b-catenin is well defined but reasons for its accumulation in HCC remain unclear. Dickkopf 4 (DKK4) acts as a negative regulator of Wnt/b-catenin pathway but its functional role in liver carcinogenesis has not been studied. We investigated the role of DKK4 in b-catenin regulation in HCC. Reduced expression of DKK4 was found in 47% (38/81) of HCC, as measured by quantitative real time PCR. Ectopic expression of DKK4 in two HCC cell lines, PLC/PRF/5 (PLC) and MHCC97L (97L), attenuated b-catenin responsive luciferase activity, and decreased both b-catenin and cyclin D1 protein levels. To study the effect of DKK4 on cell growth and tumourigenicity, two stable HCC cell lines were established from PLC and 97L cells. Functional assays demonstrated that overexpression of DKK4 hampered cell proliferation, reduced colony formation and retarded cell migration. When DKK4-expressing 97L stable cells were used to induce tumour xenografts in nude mice (n ¼ 8), reduction in tumour sizes was observed (P ¼ 0.027). Furthermore, immunohistochemical studies showed that decreased expression of DKK4 was associated with b-catenin accumulation in HCC tissues. Additionally, inhibition of the proteasome using specific inhibitor in DKK4-expressing 97L stable cells masked the effect of b-catenin. Our findings suggest a potential tumour suppressive role of DKK4 as well as that of an important regulator of HCC.
Introduction
Liver cancer ranks as the second and sixth leading cause of cancer death worldwide in men and women, respectively, and hepatocellular carcinoma (HCC) accounts for 70-80% of total liver cancers (Jemal et al., 2011) . HCC associates a dismal prognosis because of late presentation of the disease and high risk of postoperative tumour recurrence (Hao et al., 2009) . Although the risk factors for HCC are well known (Kemp et al., 2005) , the cellular and molecular mechanisms contributing to hepatocarcinogenesis are poorly understood. The Wnt/b-catenin pathway is critical for embryonic development, cell proliferation, survival, selfrenewal and regeneration (Gonzalez, 2006; Nejak-Bowen and Monga, 2011) . However, its deregulation is a hallmark of several cancers including HCC (Inagawa et al., 2002) . Surplus b-catenin in the cytoplasm is phosphorylated by a multiprotein destruction complex consisting of glycogen synthase kinase 3b (GSK3b), Axin and adenomatous polyposis coli (APC). The phosphorylated b-catenin is then ubiquitinated and degraded by the proteasome (Orford et al., 1997; MacDonald et al., 2009) . Upon binding of Wnt to one of the members of the frizzled family receptors and to the low-density lipoprotein-related protein-5 (LRP5) or LRP6 co-receptors, the phosphorylation and degradation of b-catenin is inhibited, and it accumulates in the cytoplasm and translocates to the nucleus (Zeng et al., 2005) . Inside the nucleus, b-catenin forms a complex with T-cell factor (TCF)/lymphoid enhancer factor and upregulates target genes that are implicated in cancer development for example, c-Myc and cyclin D1 (Logan and Nusse, 2004) .
Although Wnt/b-catenin signalling is frequently activated in HCC, reasons for its activation are not well understood. Somatic mutations of b-catenin have only been observed in 12-26% of HCC (de La Coste et al., 1998; Wong et al., 2001) , but cytoplasmic and nuclear accumulation of b-catenin have been reported more commonly in 40-70% of HCC (Huang et al., 1999; Wong et al., 2001) . Mutations of other Wnt/b-catenin signalling components like Axin1 and Axin2 have only been observed in 10% and 3% of HCC cases, respectively (Taniguchi et al., 2002) . Furthermore, inactivating mutations of APC are unlikely to contribute significantly as they are very rare (Chen et al., 1998) , implying that other undefined mechanisms may contribute to Wnt/b-catenin activation in HCC.
The dickkopf (DKK) family is important for vertebrate development and comprises four secreted glycoproteins (DKK1, DKK2, DKK3 and DKK4) of 255-350 amino acids (Niehrs, 2006) . They are classified as inhibitors of Wnt/b-catenin signalling but members of the DKK family exert different effects on Wnt/b-catenin signalling, and their mechanism of action has not been fully delineated . With the exception of DKK3, whose receptor has not been identified, DKK1, DKK2 and DKK4 compete with frizzled family receptors binding to the extracellular domain of LRP5/ LRP6 receptor complex in response to attenuation of Wnt activity (Krupnik et al., 1999; Semenov et al., 2001; Niehrs, 2006) . DKK1, DKK2 and DKK4 also bind to Kremens, another class of transmembrane receptors (Mao et al., 2002; Mao and Niehrs, 2003; Nakamura and Matsumoto, 2008) , although the exact mechanism of how Krm-DKKs-LRP6 complex inhibit Wnt activity has not been defined. DKK1 is an antagonist of the Wnt/b-catenin pathway and also a downstream target of Wnt/b-catenin signalling (Niida et al., 2004; Chamorro et al., 2005; Gonzalez-Sancho et al., 2005) . However, in HCC its negative feedback mechanism is abrogated and overexpression of DKK1 in HCC has been associated with cytoplasmic and nuclear b-catenin accumulation (Yu et al., 2009 ). DKK2 can serve as both an inhibitor and activator depending on cellular context (Mao et al., 2001) , and the role of DKK3 remains unclear. Previous study suggested DKK3 to have no effect on Wnt/bcatenin signalling (Krupnik et al., 1999) , whereas others have demonstrated nuclear accumulation of b-catenin as a result of reduced DKK3 expression in lung cancer (Yue et al., 2008) . Furthermore, DKK2 and DKK3 are both methylated in HCC and their methylation is more frequent in HCC tissues compared with their matched non-cancerous cirrhotic tissues, implying that methylation of DKK2 and DKK3 may not be an early event in HCC but may function in the progression of HCC . Additionally, methylation of DKK3 has been significantly associated with short progressionfree survival in HCC patients (Ding et al., 2009; Yang et al., 2010) . Although reduced expression of DKK4 has only been reported in HCC cell lines (Maehata et al., 2008) , its function in hepatocarcinogenesis with respect to the Wnt/b-catenin pathway has not been explored. Therefore, in this study we investigated the functional role of DKK4 in HCC.
Results
Reduced expression of DKK4 in HCC cell lines and tissues Eight HCC cell lines were evaluated for DKK4 mRNA expression using quantitative PCR (qPCR) and compared with immortalized normal hepatocytes MIHA. Marked reduction of DKK4 was found in all HCC cell lines ( Figure 1a ). To test whether the reduced expression of DKK4 in HCC cells is due to DNA methylation, representative HCC cell lines, such as Hep3B, HuH-7, PLC/PRF/5 (PLC) and MHCC97L (97L), were treated with increasing concentrations of 5-azacytidine, a pharmacological inhibitor of DNA methyltransferase to rule out the effects of DNA methylation. Figure 1b illustrates unaltered DKK4 expression following treatment with 5-azacytidine, suggesting other reasons for its reduced expression in HCC. We next checked the expression of DKK4 in 81 matched pairs of HCC tumours and their corresponding adjacent non-tumour liver tissues of the same patient. DKK4 was reduced in 47% (38/81) of HCC tumour tissues (Figure 1c) . (Figure 2b ). The DKK4 antibody specificity was confirmed by peptide blocking experiments as shown by western blot and immunohistochemical analysis (Supplementary Figure 1 ). We next studied the effect of DKK4 on cytoplasmic and nuclear levels of b-catenin. Ectopic expression of DKK4 in PLC and 97L cell lines resulted in a significant reduction of cytoplasmic b-catenin but the change in nuclear b-catenin protein levels was not significant as shown in the western blots ( Figure 2c ). Altogether, these results suggest that DKK4 reduces TCF-mediated luciferase activity of wild-type b-catenin but not that of mutant b-catenin. Furthermore, the reduction of b-catenin protein levels implicates that DKK4 may effect as a potential negative regulator to attenuate the Wnt/b-catenin pathway.
DKK4 exhibits tumour suppressive ability
The reduced expression of DKK4 in HCC tissues prompted us to investigate whether DKK4 acts as a tumour suppressor. Two DKK4-overexpressing stable cell lines (PLC_DKK4 and 97L_DKK4) and two control-vector stable cell lines (PLC_vec and 97L_vec) were established and DKK4 expression was confirmed using western blot (Figure 3a) . The tumour suppressive function of DKK4 was assessed in these stable cell lines by in vitro MTT proliferation assay, colony formation assay and wound-healing assay. PLC_DKK4 and 97L_DKK4 cells significantly reduced cell proliferation (Po0.05, Figure 3b ) and formed fewer colonies (Po0.05, Figure 3c ) compared with the vector-carrying stable transfectants. The wound-healing assay demonstrated that DKK4-overexpressing stable clones showed retarded migration towards the wound when compared with the vector control cells (Figure 3d ).
DKK4 suppresses in vivo tumourigenicity
To further explore the in vivo tumour suppressive ability of DKK4, tumour formation in nude mice was assessed by s.c. injection of 97L_DKK4 cells and 97L_vec cells. All mice were observed for 8 weeks. Of considerable interest, tumours derived from 97L_DKK4 cells grew substantially slower compared with tumours derived from 97L_vec cells during the entire tumour growth period ( Figure 4a ). Within 10 days, solid tumours were visible in all mice injected with 97L_vec cells. On the contrary, no tumours were observed in mice injected with 97L_DKK4 cells at 4-5 weeks, and one mouse did not develop any tumour at 8 weeks, after s.c. injection. As shown by qPCR, tumours derived from 97L_DKK4 had reduced b-catenin and cyclin D1 mRNA levels compared with tumours derived from 97L_vec cells (Figure 4b ). These results suggest that DKK4 has an important role in suppressing tumour growth with a regulatory effect on b-catenin signalling. Subsequently, we performed immunohistochemical analysis for DKK4 in tumour xenografts and confirmed that DKK4 protein was highly expressed in tumours of mice that had 97L_DKK4 cells. We next investigated the effect of DKK4 overexpression on the Wnt/b-catenin pathway in vivo. Immunohistochemical analysis on tumour xenografts showed that tumours from 97L_vec cells had strong cytoplasmic and nuclear b-catenin accumulation as well as strong cyclin D1 expression, whereas tumours from 97L_DKK4 cells had a reduced b-catenin accumulation in both the cytoplasm and the nucleus, and these tumours also exhibited reduced cyclin D1 levels ( Figure 4c ). These results suggest that DKK4 attenuates the Wnt/b-catenin pathway and has an important regulatory role in tumourigenesis in HCC.
HCC tissues with b-catenin accumulation show reduced DKK4 expression
The reduced accumulation of b-catenin in tumours of mice that had 97L_DKK4 cells, led us to investigate whether DKK4 protein expression affected b-catenin accumulation in HCC tissues. By immunohistochemical analysis, DKK4 levels were reduced in 24 out of 41 (58%) tumour tissues compared with corresponding adjacent non-tumour liver tissues. b-Catenin accumulation was detected in 29 out of 41 (71%) HCC tumour tissues compared with corresponding adjacent nontumour liver tissues. Nuclear staining of b-catenin was detected in 7 cases, with the rest showing strong staining in the cytoplasm and the cell membrane. Furthermore, of the 24 cases that showed reduced DKK4 levels, b-catenin accumulation was detected in 20 cases ( Figure 5 ) and this was statistically significant (P ¼ 0.035) (Supplementary Figure 2) .
GSK3b and the proteasome are involved in DKK4-mediated b-catenin degradation As DKK4-overexpressing cells reduced b-catenin levels, we further investigated whether DKK4 affected other components of the Wnt/b-catenin pathway. As shown in Figure 6a , compared with 97L_vec cells, 97L_DKK4 cells have reduced levels of active form of b-catenin (dephosphorylated on Ser37 or Thr41), which mediates target gene activation. DKK4 overexpression also resulted in an increase in phosphorylated b-catenin (phospho-b-catenin). This form of b-catenin is targeted for degradation. Furthermore, the effect of DKK4 on b-catenin was also blocked in the presence of proteasome inhibitor MG132, implying that DKK4 promotes degradation of b-catenin through the proteasome Figure 2 DKK4 inhibits TCF reporter activity, and reduces b-catenin and cyclin D1 protein levels. (a) PLC and 97L cells were grown in 6 well-plates and co-transfected with TOPflash or FOPflash, wild-type b-catenin or mutant b-catenin, DKK4 and pRL-TK. Normalized luciferase activity was measured 48 h after transfection, and reduced luciferase activities were observed in cells transfected with DKK4 and wild-type b-catenin, but there was no effect associated with cells transfected with DKK4 and mutant b-catenin. **Po0.005. At 48 h after DKK4 transfection, reduction in b-catenin and cyclin D1 protein levels (b) and cytoplasmic b-catenin levels (c) were observed in PLC and 97L cells using western blot. Western blot bands were quantified by Image J Software National Institutes of Health Bethesda, MD, USA following normalization to b-actin. Figure 3 Ectopic expression of DKK4 inhibits cell growth, colony formation and cell mobility in cultured HCC cells. (a) Two stable cell lines overexpressing DKK4 (PLC_DKK4 and 97L_DKK4) and control vector (PLC_vec and 97L_vec) were established in PLC and 97L cells. High level of DKK4 protein level was observed in stable cell lines using western blot. Western blot bands were quantified by Image J Software, following normalization to b-actin. (b) Equal numbers of DKK4 and vector-transfected stable cells were plated in 96-well plates, and cell proliferation was quantified by MTT assay for 4 days. Reduced cell proliferation was observed in DKK4-expressing stable cells. *Po0.05, a, P ¼ 0.024, b, P ¼ 0.019, c, P ¼ 0.017, d, P ¼ 0.029, e, P ¼ 0.036 (c) For colony formation assay, DKK4 and vector-transfected stable cells were seeded in 6-well plates and colonies were visualized by crystal violet staining after 14 days. Fewer numbers of colonies were found in DKK4-expressing stable cells. *Po0.05. (d) Cell migration was assessed by wound-healing assay. DKK4 and vector-transfected stable cells were grown to confluency in cell monolayer after which a wound was made and cell migration was monitored at 0, 24 and 48 h. DKK4-expressing stable cells migrated slower towards the wound when compared with vector-transfected stable cells. Wound sizes were measured at each time point to calculate the percentage of wound closure, using the formula below, for vector and DKK4-transfected stable cells. *Po0.05, (T 0 hr ÀT 24 hr or 48 hr /T 0 hr ) Â 100.
Action of DKK4 on Wnt/b-catenin pathway S Fatima et al system ( Figure 6b ). As GSK3b is crucial in b-catenin phosphorylation and its eventual degradation, total GSK3b levels were also examined. Although no changes in total GSK3b levels were observed, 97L_DKK4 cells showed a reduction in phosphorylated GSK3b (phospho-GSK3b, inactive form of GSK3b) compared with 
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Non-tumour Tumour an inhibitor of GSK3b activity. As shown in Figure 6c , incubation with lithium chloride blocked the ability of DKK4 to reduce b-catenin levels. Nevertheless, it is also likely that the effect of DKK4 on b-catenin phosphorylation is mediated through GSK-3a as well as GSK-3b, as lithium chloride affects both forms equivalently and b-catenin is subjected to equal control by these two isoforms.
Discussion DKK4 has been reported as a negative regulator of Wnt/ b-catenin signalling pathway (Krupnik et al., 1999) but its role in HCC is unknown. To our knowledge, the present study is the first to demonstrate reduced expression of DKK4 in HCC cell lines as well as clinical samples and its suppressive effect on tumourigenesis by influencing the Wnt/b-catenin pathway. We found DKK4 was not detectable in HCC cell lines (albeit to a low level in HepG2, a hepatic adenoma cell line) and that reduced expression was detected in 47% of HCC tissues compared with their corresponding non-tumour liver tissues. Moreover, we propose DKK4 as a negative regulator of HCC cell growth as demonstrated by the functional studies. Ectopic expression of DKK4 in malignant HCC cells resulted in inhibition of cell growth, colony formation and cell migration in vitro as well as reduction of in vivo tumourigenicity in HCC xenograft mouse model. This is also the first study to demonstrate reduced expression of DKK4 relating to b-catenin accumulation in HCC tissues. Despite the potential tumour suppressive role shown in animal and in vitro studies, DKK4 expression in clinical samples was not significantly associated with any clinicopathological parameters studied. This is in agreement with a recent study on renal cell carcinoma, which did not find any clinical association with DKK4 expression (Hirata et al., 2011) . Conceivably, there may be other confounding factors (for example, oncogenic mutations of b-catenin) affecting the DKK4 tumour suppression functions in clinical tissues that deems necessary for further investigation. Epigenetic inactivation by DNA methylation is an important mechanism of gene silencing in human cancers. However, such changes have been reported for all DKK family members with the exception of DKK4 (Sato et al., 2007; Hirata et al., 2009; Yang et al., 2010) . Frequent downregulation of DKK1-DKK3 have been reported in gastrointestinal and colorectal cancers because of promoter methylation, and Yang et al. (2010) reported methylation in DKK2 and DKK3 in HCC (Aguilera et al., 2006; Sato et al., 2007) . However, our result from HCC cell lines suggests that hypermethylation does not seem to be responsible for the downregulation of DKK4 in HCC. Similarly, Baehs et al. (2009) did not report any CpG islands in DKK4 promoter in colorectal cancer. This suggests that reasons other than methylation could be responsible for the reduced expression of DKK4. One possible reason for the reduced DKK4 expression could be because of allelic imbalance. DKK4 is located on chromosome 8p11.2-p11.1, Action of DKK4 on Wnt/b-catenin pathway S Fatima et al and this chromosome experiences frequent loss of heterozygosity in many cancers including HCC (Pineau et al., 1999) . Chromosome 8p is also home to several candidate tumour suppressor genes including deleted in liver cancer 1 (Yuan et al., 1998) , fasciculation and elongation protein zeta-1 (Ishii et al., 1999) and lipid transfer proteins (Liao et al., 2000) . The commonly deleted regions in HCC have been identified at 8p21.3-p22 and 8p23, but the recent identification of 8p11.2 as a region harbouring metastatic tumour suppressor genes makes it a likely candidate region to study DKK4 allelic imbalance. Thus, further investigation is warranted to understand the mechanisms that lead to DKK4 inactivation.
Our results show that DKK4 reduces only cytoplasmic b-catenin levels and does not affect nuclear bcatenin levels in vitro. This suggests that DKK4 may not be sufficient to suppress the Wnt/b-catenin pathway on its own and may require additional suppressive components to attenuate Wnt/b-catenin signalling. Krieghoff et al. (2006) reported that b-catenin localization in the cytoplasm and its subsequent translocation to the nucleus could be governed by competition between cytoplasmic and nuclear retention factors (for example, BCL9, APC, Axin and TCF4) for b-catenin. DKK4 also contains TCF-binding sites (Baehs et al., 2009) As a negative regulator and downstream target of Wnt/ b-catenin signalling, DKK4 like DKK1 provides a negative feedback loop that is important for regulating Wnt/b-catenin signalling in normal tissues (Krupnik et al., 1999; Pendas-Franco et al., 2008) . Thus, loss of DKK4 expression in HCC may provide cancer cells with a growth advantage. However, overexpression of DKK4 in colon cancer and renal cell carcinoma suggests that DKK4 may have tissue-specific functions or may serve roles other than regulating the Wnt/b-catenin pathway.
Cytoplasmic and/or nuclear accumulation of b-catenin is a hallmark of aberrant Wnt/b-catenin signalling, and this is the first study to suggest that inactivation of DKK4 may influence the Wnt/b-catenin pathway in HCC. HCC clinical samples with b-catenin accumulation showed reduced DKK4 expression. Reduced expression of bcatenin and cyclin D1 were also found in tumour xenografts with high DKK4 expression. Interestingly, Matsui et al. (2009) recently associated upregulation of DKK4 to b-catenin accumulation in colorectal cancer. Our results also show that HCC stable cell line overexpressing DKK4 has unaltered levels of total GSK3b but shows reduced levels of phospho-GSK3b (inactive GSK3b). GSK3b is a protein kinase associated with the destruction complex for b-catenin degradation. This suggests that active GSK3b is important for b-catenin phosphorylation and DKK4-mediated b-catenin reduction. This is also supported by the luciferase assay, which shows that DKK4 reduces TCF-mediated luciferase activity of wild-type b-catenin but has no effect on bcatenin containing mutation at Ser45. Mutation at Ser45 renders GSK3b unable to phosphorylate b-catenin at Ser33/Ser37/Thr41, thus leading to b-catenin stabilization (Sakanaka, 2002) . Additionally, treatment of HCC cells overexpressing DKK4 with MG132, a proteasome inhibitor, masked the effect of DKK4 on b-catenin. This is a novel mechanism identified in HCC. Further studies are warranted to understand the molecular mechanism leading to DKK4-mediated b-catenin reduction. Yamamoto et al. (2008) recently demonstrated a clathrindependent internalization of LRP6 for DKK1 inhibition of Wnt/b-catenin signalling. However, contrary to results of Yamamoto et al. (2008) , Blitzer et al. (2006) used mouse fibroblast cells to show that clathrin-dependent internalization of Wnt is required to propagate Wnt/bcatenin signalling and disturbing the clathrin-mediated endocytosis blocks Wnt/b-catenin activity. These recent findings suggest that mechanisms of DKK antagonistic activity may vary in different cell types.
Among the several antagonists of the Wnt/b-catenin pathway that have been identified, including Cerberus, DKKs, secreted frizzled-related protein (SFRP), SOST, Wnt inhibitory factor-1 (WIF-1) and Wise, only sFRP, WIF-1 and DKK1 have been reported to attenuate Wnt/b-catenin signalling in HCC (Shih et al., 2007; Hu et al., 2009; Yu et al., 2009) . Additionally, we and others have shown a correlation between an increase in DKK1 serum and transcript level in HCC with b-catenin accumulation resulting in poor prognosis (Yu et al., 2009; Tung et al., 2011) . Being an antagonist of Wnt/b-catenin signalling and also a downstream target of b-catenin, the overexpression of DKK1 has been proposed to be a result of dysregulated Wnt/b-catenin signalling in HCC or due to an abrogated negative feedback mechanism (Yu et al., 2009) . Few studies have associated frequent methylation of DKK2 and DKK3 in HCC to poor prognosis (Ding et al., 2009; Yang et al., 2010) implying their roles as prognostic markers. However, contrary to DKK1 and DKK4, which affect b-catenin accumulation, DKK2 and DKK3 have not been studied in the context of b-catenin upregulation in HCC and furthermore, DKK3 neither affects TCF-mediated luciferase activity nor does ectopic overexpression of DKK3 in immortalized normal hepatocytes, (MIHA cell line), affect b-catenin protein levels in vitro (Fatima S et al, unpublished data) . Thus, despite of belonging to the same family, different DKKs may serve different functions in HCC. Other antagonists of Wnt, including WIF-1 (Ding et al., 2009) and SFRPs (Takagi et al., 2008) are epigenetically silenced in HCC, and their association to b-catenin upregulation in HCC has not been reported. Although different Wnt antagonists have different expression and clinical association in HCC, the combined expression of some of these antagonists may give a better understanding of their prognostic significance in HCC. Recently, Urakami et al. (2006) reported that combined methylation analysis of several Wnt antagonists (DKK3, WIF-1 and sFRPs) can serve as tumour marker for diagnosis and prognosis for renal cell carcinoma. Further work is needed to delineate the mechanisms for the differing expression of DKKs in HCC and also to assess their tumour suppressive (or oncogenic) roles in hepatocarcinogenesis.
Altogether, we have shown reduced expression of DKK4 in HCC and its tumour suppressive properties both in vitro and in vivo, suggesting its role as an important regulator of HCC. Although several studies have highlighted the tumourigenic and prognostic significance of aberrant Wnt/b-catenin signalling in HCC, the reasons for its aberrant activation require further mechanistic investigations. DKK4 may serve as a promising target for cancer treatment, though detailed study is necessary to delineate how this antagonist exerts its antitumour effects.
Materials and methods

Human liver cell lines and clinical tissues
Immortalized human hepatocytes (MIHA) and eight HCC cell lines, HepG2, Hep3B, HuH-7, PLC, H2P, H2M, 97L and MHCC97H (97H), were cultured in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum (Invitrogen) and 1% penicillin and streptomycin (Invitrogen), as described previously (Liu et al., 2009; Lee et al., 2010) . Cultures were maintained in a humidified incubator at 37 1C with 5% carbon dioxide.
A total of 81 pairs of tumour and adjacent non-tumour liver tissues were obtained from patients with primary HCC resected at Queen Mary Hospital, Hong Kong between 1993 . Consent regarding the use of clinical specimens for this study was obtained from Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. Demographic data and clinicopathological features of the patients are summarized in Supplementary   Table 2 . Tissue samples were snap-frozen in liquid nitrogen immediately after resection and stored in À80 1C until used, as described previously (Yi et al., 2008) .
Real-time qPCR
Total RNA was isolated using TRIzol reagent (Invitrogen) and the residual genomic DNA was removed by treating the RNA samples with DNase I (Applied Biosystems, Foster City, CA, USA). RNA pellets were then dissolved in diethylpyrocarbonate-treated water and stored at À80 1C before use. Reverse transcription and qPCR were performed as described previously . Total RNA (1 mg) was reverse transcribed into cDNA using TaqMan Reverse Transcription Reagents (Applied Biosystems). qPCR was performed using SYBR Green PCR Master Mix (Invitrogen) in a 7900HT Sequence Detection Systems (Applied Biosystems) using primers for DKK4 (forward: 5 0 -CCA GAA AGT TCT GCC TCC AG-3 0 and reverse: 5 0 -CTT CTG CAT GTG TGC CAT CT-3 0 ). All reactions were performed in duplicates under the following cycling conditions: 50 1C for 2 min, 95 1C for 10 min, 40 cycles of 95 1C for 15 s and 60 1C for 1 min. The relative mRNA expression was normalized using glyceraldehyde 3-phosphate dehydrogenase as an internal control. 2-(delta) (delta)Ct method was used to calculate the fold change in gene expression between HCC tissues and their corresponding nontumour liver tissues, as described previously (Yi et al., 2008) . HCC tissue with DKK4 expression less than twofold of the non-tumour liver tissue was defined as negative for DKK4 expression (DKK4À), and those with more than twofold expression of the non-tumour liver tissue was defined as positive for DKK4 expression (DKK4 þ ).
5-azacytidine treatment
HCC cells were seeded in a 6-well plate 24 h before treatment. Cells were then treated with 0 mM, 5 mM and 10 mM 5-azacytidine (Sigma-Aldrich, St Louis, MO, USA) for 48 h. Drugs and culture medium were refreshed daily.
Dual luciferase assay
Dual luciferase assay was performed as previously described (Liu et al., 2009) . Briefly, cells were co-transfected, using Lipofectamine 2000 (Invitrogen), with TCF Reporter Plasmid (TOPflash) (Millipore, Billercia, MA, USA) or those with mutant TCFbinding sites (FOPflash) (Millipore) along with the transfection control Renilla Luciferase Reporter Vector (pRL-TK) (Promega, Madison, WI, USA). In some experiments, cells were cotransfected with DKK4 and wild-type b-catenin (Morin et al., 1997) (Addgene plasmid 16518) or mutant b-catenin (Morin et al., 1997) (with a 3 bp deletion at amino-acid Ser45) (Addgene plasmid 16520) (Addgene, Cambridge, MA, USA). At 48 h after transfection, cells were collected and suspended in Reporter Lysis Buffer (Promega) and luciferase activities were measured using reagents in Dual-Luciferase Reporter Assay System (Promega) and a luminometer.
Preparation of cytoplasmic and nuclear extracts Cytoplasmic and nuclear extracts were prepared as described previously (Dignam et al., 1983) . Briefly, confluent cells from 60 mm dishes were washed twice with cold phosphate-buffered saline and resuspended in buffer A (10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol and 0.5 mM phenylmethanesulfonylfluoride) with 0.3% Nonidet P-40, incubated on ice for 15 min and centrifuged at 2000 g for 10 min at 4 1C. The supernatant was collected, which represented the cyto-plasmic extract. The nuclear pellet was resuspended in buffer C (20 mM HEPES, pH 7.9, 25% (v/v) glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol and 0.5 mM phenylmethanesulfonylfluoride), incubated on ice for 30 min with occasional mixing and centrifuged at 20 000 g for 15 min. The supernatant represented the nuclear extract. The cytoplasmic and nuclear extracts were stored at À80 1C until used for subsequent western blot analysis.
Western blot
Cell lysates were extracted using radioimmunoprecipitation assay buffer (150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) and protein levels were detected following the procedure as described previously (Lu et al., 2011) . b-Actin was used as a loading control for each sample. The antibodies used for western blot, along with their dilutions, included b-actin (1:5000, Sigma-Aldrich), b-catenin (1:1000, Cell Signaling Technology, Danvers, MA, USA), active b-catenin (1:1000, Millipore), phosphorylated b-catenin (Thr41/Ser45) (1:1000, Cell Signaling Technology), total GSK3b (1:1000, Cell Signaling Technology), phosphorylated GSK3b (Ser9) (1:1000, Cell Signaling Technology), cyclin D1 (1:1000, Invitrogen) and DKK4 (1:250, Abgent, San Diego, CA, USA).
Establishment of cell clones overexpressing DKK4
DKK4 expression construct used here was described in previous study (Baehs et al., 2009) . PLC and 97L cell lines were transfected with: (a) pcDNA3.1(À) vector only (PLC_vec and 97L_vec) and (b) DKK4 (PLC_DKK4 and 97L_DKK4) using Lipofectamine 2000 (Invitrogen). Transfected cells were grown in Dulbecco's modified Eagle medium with 10% foetal bovine serum with addition of 500 mg/ml G418 antibiotic (Invitrogen) for 3 weeks. For transient transfection experiment, the methodology of transfection was the same, except that no drug selection using G418 was performed. Overexpression of DKK4 was confirmed using western blot.
MTT cell proliferation assay PLC and 97L cells stably transfected with DKK4 or vector were seeded in 96-well plates at an initial cell density of 2000 cells per well in triplicates. Cell viability was assessed by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) as previously described (Liu et al., 2009) . Briefly, 10 ml MTT (5 mg/ml) was added to each well and plates were incubated at 37 1C for 3 h. After incubation, dimethyl sulfoxide was added and the colour formation was quantified by means of an enzyme-linked immunosorbent assay plate reader at 570 nm wavelength.
Wound-healing assay PLC and 97L cells stably transfected with DKK4 or vector were grown to 90% confluence in 6-well plates following the procedure as previously described (Liu et al., 2010) .
Colony-formation assay PLC and 97 L cells stably transfected with DKK4 and vector were seeded in 6-well plates at an initial cell density of 200 cells per well. Colonies were allowed to form for 2 weeks and stained with 0.05% crystal violet after methanol fixation.
Lithium chloride and MG132 treatment
In all, 97L cells stably transfected with DKK4 or vector were grown to 90% confluence in 6-well plates and were treated either with 20 mM lithium chloride (USB, Cleveland, OH, USA) or 10 mM MG132 (Sigma-Aldrich) for 12 h. Protein lysates were collected for western blot as described above.
HCC xenograft mouse model
Male athymic BALB/c nude mice were bred in the Laboratory Animal Unit, the University of Hong Kong. Institutional guidelines were followed while handling the animals. The animals were placed in a pathogen-free environment and allowed to acclimate for 1 week before being used in the study. A total of 1 Â 10 6 97L_vec cells or 97L_DKK4 cells suspended in phosphate-buffered saline (200 ml per mouse) were injected s.c. into 4-week-old nude mice. Tumour volume in mm 3 was measured weekly with digital calliper using the formula: volume ¼ (width) 2 Â length/2. Animals were killed 8 weeks after s.c. injection. The protocol was approved by the Committee on the Use of Live Animals in Teaching and Research, the University of Hong Kong.
Immunohistochemistry
Immunohistochemistry was performed as previously described with modifications (Lee et al., 2006 (Lee et al., , 2009b . Tissue sections were deparaffinized by submerging the slides in xylene and rehydrated in decreasing concentrations of ethanol (100% followed by 90 and 75%, each twice). Antigen retrieval was achieved by boiling the tissue sections in EDTA buffer (1 mM EDTA, 0.05% Tween 20, pH 8.0) in a microwave for 10 min before incubation with bcatenin (1:100, BD, Franklin Lakes, NJ, USA), DKK4 (1:200, Abgent) or cyclin D1 (1:100, Cell Signaling Technology) antibodies overnight. Sections were then incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies (Invitrogen), and diaminobenzidine (Dako, Glostrup, Denmark) was used as the chromogen. The tissue sections were scored for intensity using the criteria: 0 (no signal), 1 (weak; 10-20% positive), 2 (moderate; 20-50% positive) and 3 (strong; 450% positive).
DKK4 antibody specificity
For antibody specificity by western blot and immunohistochemical analysis, DKK4-blocking peptide (Abgent Inc.; catalogue # BP1524a) was used at a 10-fold molar excess to DKK4 antibody (Abgent), as per the manufacturer's instructions. Western blot (Lu et al., 2011) and immunohistochemical analysis (Lee et al., 2006 (Lee et al., , 2009b were performed as described previously.
Statistical analysis
The data were analysed using Prism for Windows (version 5.01) (GraphPad Software, La Jolla, CA, USA) and SPSS for Windows (version 16.0) (IBM, New York, NY, USA). Student's t-tests were used to study significant differences between different groups for in vitro and in vivo functional experiments. For clinicopathological analysis, Pearson's w
